MA38318A1 - Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer - Google Patents

Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer

Info

Publication number
MA38318A1
MA38318A1 MA38318A MA38318A MA38318A1 MA 38318 A1 MA38318 A1 MA 38318A1 MA 38318 A MA38318 A MA 38318A MA 38318 A MA38318 A MA 38318A MA 38318 A1 MA38318 A1 MA 38318A1
Authority
MA
Morocco
Prior art keywords
ionizing radiation
inorganic nanoparticles
cancer
compositions
treatment
Prior art date
Application number
MA38318A
Other languages
English (en)
Inventor
Agnès Pottier
Laurent Levy
Elsa Borghi
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA38318A1 publication Critical patent/MA38318A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1087—Ions; Protons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1089—Electrons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des nanoparticules inorganiques activables pouvant être utilisées dans le secteur de la santé, en particulier de la santé humaine, pour perturber, modifier ou détruire des cellules, tissus ou organes cibles cancéreux. Elle concerne plus particulièrement des nanoparticules pouvant générer un effet thérapeutique significativement efficace, lorsqu'elles sont concentrées à l'intérieur de la tumeur et exposées à des rayonnements ionisants. L'invention concerne également des compositions pharmaceutiques contenant un ensemble de nanoparticules telles que définies précédemment, ainsi que leurs utilisations.
MA38318A 2013-01-25 2014-01-24 Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer MA38318A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305087 2013-01-25
PCT/EP2014/051367 WO2014114732A1 (fr) 2013-01-25 2014-01-24 Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA38318A1 true MA38318A1 (fr) 2017-02-28

Family

ID=47710064

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38318A MA38318A1 (fr) 2013-01-25 2014-01-24 Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer

Country Status (23)

Country Link
US (4) US10098952B2 (fr)
EP (1) EP2948179B1 (fr)
JP (2) JP6619231B2 (fr)
KR (2) KR102385193B1 (fr)
CN (1) CN105120897B (fr)
AR (1) AR094577A1 (fr)
AU (1) AU2014209899B2 (fr)
BR (1) BR112015017490A2 (fr)
CA (2) CA3179586A1 (fr)
CY (1) CY1121838T1 (fr)
EA (1) EA034242B1 (fr)
HK (1) HK1216609A1 (fr)
IL (1) IL239767B (fr)
MA (1) MA38318A1 (fr)
MX (1) MX369664B (fr)
PL (1) PL2948179T3 (fr)
RS (1) RS59042B1 (fr)
SG (1) SG11201505277VA (fr)
SI (1) SI2948179T1 (fr)
TW (1) TW201442726A (fr)
UA (1) UA116007C2 (fr)
WO (1) WO2014114732A1 (fr)
ZA (1) ZA201505510B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6042450B2 (ja) 2011-12-16 2016-12-14 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
CA3179586A1 (fr) 2013-01-25 2014-07-31 Nanobiotix Compositions de nanoparticules inorganiques combinees a des rayonnements ionisants pour le traitement du cancer
EP2886128A1 (fr) * 2013-12-20 2015-06-24 Nanobiotix Compositions pharmaceutiques comportant des nanoparticules, leur préparation et leur utilisation
US11096962B2 (en) 2015-05-28 2021-08-24 Nanobiotix Nanoparticles for use as a therapeutic vaccine
MX2019007614A (es) * 2016-12-21 2019-09-04 Nanobiotix Nanoparticulas para su uso para tratar un trastorno neuronal.
WO2018114988A1 (fr) * 2016-12-21 2018-06-28 Nanobiotix Nanoparticules destinées à être utilisées pour améliorer les performances cérébrales ou pour traiter le stress
EP3424533A1 (fr) * 2017-07-05 2019-01-09 Nh Theraguix Procédés de traitement de la dépendance
EP3654976A1 (fr) * 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Procédés d'utilisation de rayonnement à débit de dose ultra élevé et d'agents thérapeutiques
US20220249389A1 (en) * 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
WO2021011496A1 (fr) * 2019-07-12 2021-01-21 Oregon Health & Science University Constructions immunothérapeutiques et leurs procédés d'utilisation
EP3996750A4 (fr) 2019-07-12 2024-01-03 Univ Oregon Health & Science Constructions thérapeutiques pour la co-administration d'un inhibiteur de la kinase mitotique et d'un inhibiteur des points de contrôle immunitaire
WO2021215952A1 (fr) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Procédé de production de particules de bactériophages de la famille levivirus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645464B1 (en) 1998-07-30 2003-11-11 James F. Hainfeld Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
AU2002218087A1 (en) * 2000-11-20 2002-05-27 Oncolytics Biotech Inc. Method for optimally delivering virus to a solid tumor mass
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
FR2884149B1 (fr) * 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
EP2130553A1 (fr) * 2008-06-05 2009-12-09 Nanobiotix Nanoparticules inorganiques de haute densité pour détruire des cellules in-vivo
US8395131B2 (en) * 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (fr) * 2009-07-10 2011-01-19 Nanobiotix Nanoparticules métalliques, leur préparation et utilisations
WO2011127061A1 (fr) 2010-04-05 2011-10-13 Nanospectra Biosciences, Inc. Amélioration d'une thérapie par rayonnement par nanoparticules ciblées à z élevé
JP6042450B2 (ja) * 2011-12-16 2016-12-14 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
CA3179586A1 (fr) 2013-01-25 2014-07-31 Nanobiotix Compositions de nanoparticules inorganiques combinees a des rayonnements ionisants pour le traitement du cancer

Also Published As

Publication number Publication date
PL2948179T3 (pl) 2019-10-31
EP2948179A1 (fr) 2015-12-02
UA116007C2 (uk) 2018-01-25
WO2014114732A1 (fr) 2014-07-31
ZA201505510B (en) 2016-12-21
AU2014209899A1 (en) 2015-07-23
CN105120897B (zh) 2017-12-05
SI2948179T1 (sl) 2019-09-30
US11819548B2 (en) 2023-11-21
US20240100163A1 (en) 2024-03-28
IL239767B (en) 2018-10-31
US10098952B2 (en) 2018-10-16
MX369664B (es) 2019-11-14
KR102225239B1 (ko) 2021-03-09
US11020480B2 (en) 2021-06-01
HK1216609A1 (zh) 2016-11-25
CY1121838T1 (el) 2020-07-31
KR102385193B1 (ko) 2022-04-12
CA2897362A1 (fr) 2014-07-31
BR112015017490A2 (pt) 2017-07-11
US20190008962A1 (en) 2019-01-10
US20210283256A1 (en) 2021-09-16
MX2015009409A (es) 2016-03-16
CA3179586A1 (fr) 2014-07-31
TW201442726A (zh) 2014-11-16
EA201591378A1 (ru) 2016-04-29
AU2014209899B2 (en) 2018-05-24
KR20210027536A (ko) 2021-03-10
RS59042B1 (sr) 2019-08-30
AR094577A1 (es) 2015-08-12
JP2016505061A (ja) 2016-02-18
KR20150108923A (ko) 2015-09-30
JP2018168162A (ja) 2018-11-01
EP2948179B1 (fr) 2019-06-19
SG11201505277VA (en) 2015-08-28
JP6619231B2 (ja) 2019-12-11
CN105120897A (zh) 2015-12-02
CA2897362C (fr) 2023-02-14
IL239767A0 (en) 2015-08-31
US20150374818A1 (en) 2015-12-31
EA034242B1 (ru) 2020-01-21

Similar Documents

Publication Publication Date Title
MA38318A1 (fr) Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer
MA33516B1 (fr) Nanoparticules métalliques, leur préparation et leurs utilisations
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
NZ703047A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
CY1118216T1 (el) Μεθοδοι αγωγης καρκινου
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
IN2012DN02018A (fr)
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
BRPI0507039A8 (pt) composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit
CR20120625A (es) Métodos de tratamiento contra el cáncer pancreático
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2019003694A (es) Metodos para tratar cancer del tracto biliar.
WO2019043176A3 (fr) Inhibiteur de l'histone-désacétylase en association avec un agent antimétabolite pour la cancérothérapie
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.
NZ709685A (en) Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
CO2017003236A1 (es) Nueva composición a base de un compuesto natural derivado de annonaceae
EA202090551A1 (ru) Усиление эффекта от высвобождения аденозинтрифосфата (атф)